Steen Meier Knudsen
Chief Tech/Sci/R&D Officer at ALLARITY THERAPEUTICS, INC.
Profile
Steen Meier Knudsen is the founder of Medical Prognosis Institute A (founded in 2004) where he served as the Chief Executive Officer from 2004 to 2006.
He is also the founder of Allarity Therapeutics Europe ApS (founded in 2012) where he currently holds the position of Director & Chief Scientific Officer.
Additionally, he was the founder of Oncology Venture Sweden AB (founded in 2012) where he previously served as the Director & Chief Scientific Officer.
Dr. Knudsen is currently the Chief Scientific Officer at Allarity Therapeutics A (founded in 2004).
He currently holds the position of Chief Executive Officer & Director at Medical Prognosis Institute, Inc. and is the Owner of Mpi Holding ApS.
He is also the Chief Scientific Officer at Allarity Therapeutics, Inc. since 2021.
Dr. Knudsen previously worked as a Professor at the Technical University of Denmark from 2003 to 2005.
He completed his graduate degree at the Technical University of Denmark and obtained a doctorate degree from the University of Copenhagen.
Steen Meier Knudsen active positions
Companies | Position | Start |
---|---|---|
ALLARITY THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 2021-06-30 |
Allarity Therapeutics Europe ApS
Allarity Therapeutics Europe ApS Pharmaceuticals: MajorHealth Technology Allarity Therapeutics Europe ApS operates as a pharmaceutical company that provides oncology products. The firm engages in diagnostics and drug development. The company was founded by Steen Meier Knudsen on August 1, 2012 and is headquartered in Hørsholm, Denmark. | Founder | 2012-07-31 |
Medical Prognosis Institute, Inc. | Chief Executive Officer | - |
Allarity Therapeutics A/S
Allarity Therapeutics A/S Pharmaceuticals: MajorHealth Technology Allarity Therapeutics A/S is a biotechnology company, which engages in the research and development of anti-cancer drugs. Its product pipeline includes LiPlaCis, 2X-121, 2X-111, irofulven phase 2, and APO010.The company was founded by Steen Meier Knudsen and Peter Buhl Jensen in 2004 and is headquartered in Hoersholm, Denmark. | Founder | 2003-12-31 |
Mpi Holding ApS | Corporate Officer/Principal | - |
Former positions of Steen Meier Knudsen
Companies | Position | End |
---|---|---|
Technical University of Denmark | Corporate Officer/Principal | 2004-12-31 |
Oncology Venture Sweden AB
Oncology Venture Sweden AB BiotechnologyHealth Technology Oncology Venture Sweden AB engages in research and development of anti-cancer drugs through its subsidiary Oncology Ventures ApS. It focuses on diagnostics and development of medicinal products for treatment of cancer. The company was founded by Peter Buhl Jensen, Steen Meier Knudsen, Nils Aage Brünner, and Ulla Hald Buhl on June 4, 2015 and is headquartered in Hørsholm, Denmark. | Founder | - |
Medical Prognosis Institute A/S
Medical Prognosis Institute A/S BiotechnologyHealth Technology Medical Prognosis Institute A/S engages in the research and development of drugs and treatments for cancer and other related illnesses. It operates through the following segments: X Labs, Predict, Ventures, Personal, and Diagnostic business areas. The X Labs business area offers invent, prototype, and prove relevant techniques, scientific methodologies and business models. The Predict business area utilize the method to generate drug and patient response reports. The Ventures business area focuses on business development ventures. The Personal business area engages in developing business to consumer products and services. The Diagnostic business area operates lung chip diagnostics. The company was founded by Steen Knudsen in September 2004 and is headquartered in Horsholm, Denmark. | Chief Executive Officer | 2005-12-31 |
Training of Steen Meier Knudsen
Technical University of Denmark | Graduate Degree |
University of Copenhagen | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
ALLARITY THERAPEUTICS, INC. | Health Technology |
Private companies | 6 |
---|---|
Medical Prognosis Institute A/S
Medical Prognosis Institute A/S BiotechnologyHealth Technology Medical Prognosis Institute A/S engages in the research and development of drugs and treatments for cancer and other related illnesses. It operates through the following segments: X Labs, Predict, Ventures, Personal, and Diagnostic business areas. The X Labs business area offers invent, prototype, and prove relevant techniques, scientific methodologies and business models. The Predict business area utilize the method to generate drug and patient response reports. The Ventures business area focuses on business development ventures. The Personal business area engages in developing business to consumer products and services. The Diagnostic business area operates lung chip diagnostics. The company was founded by Steen Knudsen in September 2004 and is headquartered in Horsholm, Denmark. | Health Technology |
Allarity Therapeutics Europe ApS
Allarity Therapeutics Europe ApS Pharmaceuticals: MajorHealth Technology Allarity Therapeutics Europe ApS operates as a pharmaceutical company that provides oncology products. The firm engages in diagnostics and drug development. The company was founded by Steen Meier Knudsen on August 1, 2012 and is headquartered in Hørsholm, Denmark. | Health Technology |
Medical Prognosis Institute, Inc. | |
Oncology Venture Sweden AB
Oncology Venture Sweden AB BiotechnologyHealth Technology Oncology Venture Sweden AB engages in research and development of anti-cancer drugs through its subsidiary Oncology Ventures ApS. It focuses on diagnostics and development of medicinal products for treatment of cancer. The company was founded by Peter Buhl Jensen, Steen Meier Knudsen, Nils Aage Brünner, and Ulla Hald Buhl on June 4, 2015 and is headquartered in Hørsholm, Denmark. | Health Technology |
Allarity Therapeutics A/S
Allarity Therapeutics A/S Pharmaceuticals: MajorHealth Technology Allarity Therapeutics A/S is a biotechnology company, which engages in the research and development of anti-cancer drugs. Its product pipeline includes LiPlaCis, 2X-121, 2X-111, irofulven phase 2, and APO010.The company was founded by Steen Meier Knudsen and Peter Buhl Jensen in 2004 and is headquartered in Hoersholm, Denmark. | Health Technology |
Mpi Holding ApS |
- Stock Market
- Insiders
- Steen Meier Knudsen